Hamburg, Germany, 30 January 2020:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development. Evotec will receive a milestone payment of € 2 m upon first dosing in the Phase I clinical trial and may be eligible for further significant clinical and sales milestones as well as royalties depending on the future progress during clinical development and potential commercialisation of a drug in the future.

The companies entered into their endometriosis multi-target discovery alliance in October 2012 with the aim to discover three clinical candidates. So far, the alliance generated six pre-clinical candidates, of which a fourth has now progressed into Phase I. Bayer advanced the first programme into a Phase II trial in refractory chronic cough in 2018. The Phase II study yielded positive results which met all of the targeted endpoints. For more information about this Bayer/Evotec alliance also see “White Paper on Bayer/Evotec Alliance”.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are very pleased that the excellent collaboration between Bayer and Evotec has now officially surpassed the ambitious initial target by delivering a fourth clinical drug candidate. The candidates we have identified and developed together are performing extremely well and hold great potential, most likely also beyond the initially surveyed indications.”

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.